TY - JOUR
T1 - Calcium intake and risk of colorectal cancer according to tumor-infiltrating T cells
AU - Yang, Wanshui
AU - Liu, Li
AU - Keum, Na Na
AU - Qian, Zhi Rong
AU - Nowak, Jonathan A.
AU - Hamada, Tsuyoshi
AU - Song, Mingyang
AU - Cao, Yin
AU - Nosho, Katsuhiko
AU - Smith-Warner, Stephanie A.
AU - Zhang, Sui
AU - Masugi, Yohei
AU - Ng, Kimmie
AU - Kosumi, Keisuke
AU - Ma, Yanan
AU - Garrett, Wendy S.
AU - Wang, Molin
AU - Nan, Hongmei
AU - Giannakis, Marios
AU - Meyerhardt, Jeffrey A.
AU - Chan, Andrew T.
AU - Fuchs, Charles S.
AU - Nishihara, Reiko
AU - Wu, Kana
AU - Giovannucci, Edward L.
AU - Ogino, Shuji
AU - Zhang, Xuehong
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/5
Y1 - 2019/5
N2 - Calcium intake has been associated with a lower risk 0.36–0.84; Ptrend ¼ 0.002) for CD8þ T-cell–low but not of colorectal cancer. Calcium signaling may enhance for CD8þ T-cell–high tumors (HR ¼ 1.02; 95% CI, T-cell proliferation and differentiation, and contribute 0.67–1.55; Ptrend ¼ 0.47). Similarly, the corresponding to T-cell–mediated antitumor immunity. In this pro-HRs (95% CIs) for calcium for low versus high T-cell–spective cohort study, we investigated the association infiltrated tumors were 0.63 (0.42–0.94; Ptrend ¼ 0.01) between calcium intake and colorectal cancer risk and 0.89 (0.58–1.35; Ptrend ¼ 0.20) for CD3þ; according to tumor immunity status to provide addi-0.58 (0.39–0.87; Ptrend ¼ 0.006) and 1.04 (0.69–tional insights into the role of calcium in colorectal 1.58; Ptrend ¼ 0.54) for CD45ROþ; and 0.56 (0.36–carcinogenesis. The densities of tumor-infiltrating 0.85; Ptrend ¼ 0.006) and 1.10 (0.72–1.67; Ptrend ¼ T-cell subsets [CD3þ, CD8þ, CD45RO (PTPRC)þ, or 0.47) for FOXP3þ, although the differences by sub-FOXP3þ cell] were assessed using IHC and computer-types defined by T-cell density were not statistically assisted image analysis in 736 cancer cases that devel-significant. These potential differential associations oped among 136,249 individuals in two cohorts. HRs generally appeared consistent regardless of sex, source and 95% confidence intervals (CI) were calculated of calcium intake, tumor location, and tumor micro-using Cox proportional hazards regression. Total cal-satellite instability status. Our findings suggest a pos-cium intake was associated with a multivariable HR of sible role of calcium in cancer immunoprevention via 0.55 (comparing 1,200 vs. <600 mg/day; 95% CI, modulation of T-cell function.
AB - Calcium intake has been associated with a lower risk 0.36–0.84; Ptrend ¼ 0.002) for CD8þ T-cell–low but not of colorectal cancer. Calcium signaling may enhance for CD8þ T-cell–high tumors (HR ¼ 1.02; 95% CI, T-cell proliferation and differentiation, and contribute 0.67–1.55; Ptrend ¼ 0.47). Similarly, the corresponding to T-cell–mediated antitumor immunity. In this pro-HRs (95% CIs) for calcium for low versus high T-cell–spective cohort study, we investigated the association infiltrated tumors were 0.63 (0.42–0.94; Ptrend ¼ 0.01) between calcium intake and colorectal cancer risk and 0.89 (0.58–1.35; Ptrend ¼ 0.20) for CD3þ; according to tumor immunity status to provide addi-0.58 (0.39–0.87; Ptrend ¼ 0.006) and 1.04 (0.69–tional insights into the role of calcium in colorectal 1.58; Ptrend ¼ 0.54) for CD45ROþ; and 0.56 (0.36–carcinogenesis. The densities of tumor-infiltrating 0.85; Ptrend ¼ 0.006) and 1.10 (0.72–1.67; Ptrend ¼ T-cell subsets [CD3þ, CD8þ, CD45RO (PTPRC)þ, or 0.47) for FOXP3þ, although the differences by sub-FOXP3þ cell] were assessed using IHC and computer-types defined by T-cell density were not statistically assisted image analysis in 736 cancer cases that devel-significant. These potential differential associations oped among 136,249 individuals in two cohorts. HRs generally appeared consistent regardless of sex, source and 95% confidence intervals (CI) were calculated of calcium intake, tumor location, and tumor micro-using Cox proportional hazards regression. Total cal-satellite instability status. Our findings suggest a pos-cium intake was associated with a multivariable HR of sible role of calcium in cancer immunoprevention via 0.55 (comparing 1,200 vs. <600 mg/day; 95% CI, modulation of T-cell function.
UR - http://www.scopus.com/inward/record.url?scp=85065511115&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-18-0279
DO - 10.1158/1940-6207.CAPR-18-0279
M3 - Article
C2 - 30760501
AN - SCOPUS:85065511115
SN - 1940-6207
VL - 12
SP - 283
EP - 293
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 5
ER -